For children with a kidney condition called steroid-sensitive nephrotic syndrome, the problem isn't just their kidneys. A common and dangerous complication is dyslipidemia—unhealthy levels of cholesterol and fats in the blood. This often sticks around even when the main kidney symptoms are in remission. It's a silent threat that raises the risk of early heart disease and further kidney damage. Dietary changes often aren't enough, and there's little evidence on whether cholesterol-lowering drugs called statins are safe and effective for these kids. This study aimed to fill that gap. It looked specifically at the drug atorvastatin in 100 children, aged 8 to 18, who had this kidney condition and the accompanying cholesterol problem. The main goal was to see what percentage of these children could reach healthier, target levels for their cholesterol and other blood fats after taking the drug. The study also carefully monitored for safety. The findings could provide much-needed guidance on whether this common adult medication can be a safe and useful tool to protect the long-term heart and kidney health of vulnerable children.
Can a common cholesterol drug protect children's hearts and kidneys from a hidden danger?
Plain Language Summary
What this means for you:
A cholesterol drug was tested to see if it can safely protect children with a kidney condition from heart and kidney damage. What this means for you:
A cholesterol drug was tested to see if it can safely protect children with a kidney condition from heart and kidney damage. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE4
Condition(s): Dyslipidaemia
Intervention(s): Atorvastatin (DRUG)
To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.
Detailed: Abstract Background: Dyslipidemia is a common complication in children with steroid-sensitive nephrotic syndrome (SSNS), which often persists during remission. It increases the risk of early atherosclerosis, cardiovascular disease, and progressive kidney damage. Lifestyle and dietary measures are often insufficient, and evidence on the use of statins such as atorvastatin in this population remains fairly unexplored.
Objective: To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.
Methods: This quasi-experimental study was conducted at the department of Pediatric Nephrology \& Nephrology department, National Institute of Kidney Diseases \& Urology, Dhaka. A total of 100 children aged between 8-18 years with
Primary Outcome(s): percentage of patients achieving target levels of lipid profile
Enrollment: 100 (ACTUAL)
Lead Sponsor: National Institute of Kidney Disease and Urology (NIKDU)
Start: 2024-01-27 | Primary Completion: 2025-08-30